Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation

Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation

Abstract Aims Improved cancer survivorship has led to a higher number of anthracycline‐induced cardiomyopathy patients with end‐stage heart failure. We hypothesize that outcomes following continuous‐flow LVAD (CF‐LVAD) implantation in those with anthracycline‐induced cardiomyopathy are comparable wi...

Full description

Bibliographic Details
Main Authors: Avirup Guha, Cesar Caraballo, Prantesh Jain, P. Elliott Miller, Jocelyn Owusu‐Guha, Katherine A.A. Clark, Eric J. Velazquez, Tariq Ahmad, Lauren A. Baldassarre, Daniel Addison, Neal L. Weintraub, Nihar R. Desai
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:ESC Heart Failure
Subjects:
INTERMACS
Anthracycline
Continuous‐flow LVAD
Bleeding
Stroke
Mortality
Online Access:https://doi.org/10.1002/ehf2.13362

Internet

https://doi.org/10.1002/ehf2.13362

Similar Items